Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis

Detalhes bibliográficos
Autor(a) principal: Canhão, Helena
Data de Publicação: 2012
Outros Autores: Rodrigues, Ana Maria, Mourão, Ana Filipa, Martins, Fernando, Santos, Maria José, Canas-silva, José, Polido-pereira, Joaquim, Silva, José Alberto Pereira, Costa, José António, Araújo, Domingos, Silva, Cândida, Santos, Helena, Duarte, Cátia, Da silva, José Antonio Pereira, Pimentel-santos, Fernando M., Branco, Jaime, Karlson, Elizabeth W., Fonseca, João Eurico, Solomon, Daniel H.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/149794
Resumo: Funding Information: positions on two Pfizer sponsored trials and has directed an educational course supported by Bristol Myers Squibb. He serves as an epidemiology consultant to CORRONA. J.A.P.S. has received honoraria as a speaker or consultant and benefited from research support from several pharmaceutical companies involved in the production of biologic agents (Abbott, Amgen, MSD, Pfizer and Roche), always at sums less than E10 000. All other authors have declared no conflicts of interest. Funding Information: Funding: This work was supported by a grant from Harvard-Portugal Program HMSP-ICS/SAU-ICT/0002/ 2010.
id RCAP_5a2bace31dbafcd776610026e4af4822
oai_identifier_str oai:run.unl.pt:10362/149794
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritisComparative effectivenessRAResponse predictorsReuma.pt registerTNF inhibitorsRheumatologyPharmacology (medical)Funding Information: positions on two Pfizer sponsored trials and has directed an educational course supported by Bristol Myers Squibb. He serves as an epidemiology consultant to CORRONA. J.A.P.S. has received honoraria as a speaker or consultant and benefited from research support from several pharmaceutical companies involved in the production of biologic agents (Abbott, Amgen, MSD, Pfizer and Roche), always at sums less than E10 000. All other authors have declared no conflicts of interest. Funding Information: Funding: This work was supported by a grant from Harvard-Portugal Program HMSP-ICS/SAU-ICT/0002/ 2010.Objectives: Adalimumab, etanercept and infliximab are effective TNF inhibitors (TNFis) in the treatment of RA, but no randomized clinical trials have compared the three agents. Prior observational data are not consistent. We compared their effectiveness over 1 year in a prospective cohort.Methods: Analyses were performed on subjects' first episode of TNFi use in the Rheumatic Diseases Portuguese Register, Reuma.pt. The primary outcome was the proportion of patients with European League Against Rheumatism good response sustained at two consecutive observations separated by 3 months during the first year of TNFi use. Comparisons were performed using conventional adjusted logistic regression, as well as matching subjects across the three agents using a propensity score. In addition, baseline predictors of treatment response to TNFi were identified.Results: The study cohort included 617 RA patients, 250 starting etanercept, 206 infliximab and 161 adalimumab. Good response was achieved by 59.6% for adalimumab, 59.2% for etanercept and 51.9% for infliximab (P = 0.21). The modelled probability of good response did not significantly differ across agents (etanercept vs adalimumab OR = 0.97, 95% CI 0.55, 1.71; etanercept vs infliximab OR = 1.25, 95% CI 0.74, 2.12; infliximab vs adalimumab OR = 0.80, 95% CI 0.47, 1.36). Matched propensity score analyses also showed no significant treatment response differences. Greater educational attainment was a predictor of better response, while smoking, presence of ACPA, glucocorticoid use and worse physician assessment of disease activity at baseline each predicted a reduced likelihood of treatment response.Conclusion: Over 1 year, we found no difference in effectiveness between adalimumab, etanercept and infliximab.Centro de Estudos de Doenças Crónicas (CEDOC)NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNCanhão, HelenaRodrigues, Ana MariaMourão, Ana FilipaMartins, FernandoSantos, Maria JoséCanas-silva, JoséPolido-pereira, JoaquimSilva, José Alberto PereiraCosta, José AntónioAraújo, DomingosSilva, CândidaSantos, HelenaDuarte, CátiaDa silva, José Antonio PereiraPimentel-santos, Fernando M.Branco, JaimeKarlson, Elizabeth W.Fonseca, João EuricoSolomon, Daniel H.2023-02-27T22:22:57Z2012-112012-11-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article7application/pdfhttp://hdl.handle.net/10362/149794eng1462-0324PURE: 49089688https://doi.org/10.1093/rheumatology/kes184info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:31:38Zoai:run.unl.pt:10362/149794Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:53:51.761535Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
title Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
spellingShingle Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
Canhão, Helena
Comparative effectiveness
RA
Response predictors
Reuma.pt register
TNF inhibitors
Rheumatology
Pharmacology (medical)
title_short Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
title_full Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
title_fullStr Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
title_full_unstemmed Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
title_sort Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
author Canhão, Helena
author_facet Canhão, Helena
Rodrigues, Ana Maria
Mourão, Ana Filipa
Martins, Fernando
Santos, Maria José
Canas-silva, José
Polido-pereira, Joaquim
Silva, José Alberto Pereira
Costa, José António
Araújo, Domingos
Silva, Cândida
Santos, Helena
Duarte, Cátia
Da silva, José Antonio Pereira
Pimentel-santos, Fernando M.
Branco, Jaime
Karlson, Elizabeth W.
Fonseca, João Eurico
Solomon, Daniel H.
author_role author
author2 Rodrigues, Ana Maria
Mourão, Ana Filipa
Martins, Fernando
Santos, Maria José
Canas-silva, José
Polido-pereira, Joaquim
Silva, José Alberto Pereira
Costa, José António
Araújo, Domingos
Silva, Cândida
Santos, Helena
Duarte, Cátia
Da silva, José Antonio Pereira
Pimentel-santos, Fernando M.
Branco, Jaime
Karlson, Elizabeth W.
Fonseca, João Eurico
Solomon, Daniel H.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Centro de Estudos de Doenças Crónicas (CEDOC)
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Canhão, Helena
Rodrigues, Ana Maria
Mourão, Ana Filipa
Martins, Fernando
Santos, Maria José
Canas-silva, José
Polido-pereira, Joaquim
Silva, José Alberto Pereira
Costa, José António
Araújo, Domingos
Silva, Cândida
Santos, Helena
Duarte, Cátia
Da silva, José Antonio Pereira
Pimentel-santos, Fernando M.
Branco, Jaime
Karlson, Elizabeth W.
Fonseca, João Eurico
Solomon, Daniel H.
dc.subject.por.fl_str_mv Comparative effectiveness
RA
Response predictors
Reuma.pt register
TNF inhibitors
Rheumatology
Pharmacology (medical)
topic Comparative effectiveness
RA
Response predictors
Reuma.pt register
TNF inhibitors
Rheumatology
Pharmacology (medical)
description Funding Information: positions on two Pfizer sponsored trials and has directed an educational course supported by Bristol Myers Squibb. He serves as an epidemiology consultant to CORRONA. J.A.P.S. has received honoraria as a speaker or consultant and benefited from research support from several pharmaceutical companies involved in the production of biologic agents (Abbott, Amgen, MSD, Pfizer and Roche), always at sums less than E10 000. All other authors have declared no conflicts of interest. Funding Information: Funding: This work was supported by a grant from Harvard-Portugal Program HMSP-ICS/SAU-ICT/0002/ 2010.
publishDate 2012
dc.date.none.fl_str_mv 2012-11
2012-11-01T00:00:00Z
2023-02-27T22:22:57Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/149794
url http://hdl.handle.net/10362/149794
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1462-0324
PURE: 49089688
https://doi.org/10.1093/rheumatology/kes184
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 7
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138128879943680